Lilly plans expansion of local insulin plant

Eli Lilly and Co. will expand its Indianapolis manufacturing operations for the first time in more than two decades, the company announced Tuesday.

The Indianapolis-based drugmaker said the "multi-million" expansion will allow the plant to make insulin cartridges to meet what it describes as growing demand in the United States.

Lilly did not offer details about the expansion or say whether it  include new jobs.

U.S. sales of Lilly’s insulins, Humalog and Humulin, fell in Lilly’s most recent quarter by 2 percent and 7 percent, respectively. Lilly officials said the products were losing market share in the first half of the year after a large third-party payer removed Lilly’s insulins from its formulary.

Also, a contract Lilly had with Wal-Mart Stores Inc. to supply insulin for its ReliOn brand was terminated.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.